A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease

Abstract

Because of its genetic underpinnings and consistent age of onset within families, autosomal dominant Alzheimer’s disease (ADAD) provides a unique opportunity to conduct clinical trials of investigational agents as preventative or symptom-delaying treatments. The design of such trials may be complicated by low rates of genetic testing and disclosure among… (More)
DOI: 10.1186/s13195-015-0135-0

Topics

2 Figures and Tables

Cite this paper

@inproceedings{Grill2015ASO, title={A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease}, author={Joshua D Grill and Randall J. Bateman and Virginia Buckles and Angela Oliver and John C. Morris and Colin L. Masters and William E. Klunk and John M. Ringman}, booktitle={Alzheimer's Research & Therapy}, year={2015} }